EYENOVIA INC. - COMMON STOCK

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

07 Aug 2024 17:11:42 By Nasdaq GlobeNewswire

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

30 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

23 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Pricing of $5M Registered Direct Offering

28 Jun 2024 08:00:14 By Nasdaq GlobeNewswire

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

15 May 2024 16:01:00 By Nasdaq GlobeNewswire

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

25 Apr 2024 07:00:01 By Nasdaq GlobeNewswire

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

08 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

18 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

16 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

13 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

Eyenovia to Report Third Quarter 2023 Results on Monday, November 13

06 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®

09 Oct 2023 07:00:00 By Nasdaq GlobeNewswire